Adverum Biotechnologies, Inc. (ADVM)
- Previous Close
10.66 - Open
10.63 - Bid 10.26 x 100
- Ask 10.36 x 200
- Day's Range
10.30 - 10.84 - 52 Week Range
7.40 - 29.70 - Volume
177,682 - Avg. Volume
272,915 - Market Cap (intraday)
214.625M - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-11.60 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.33
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
adverum.comRecent News: ADVM
Performance Overview: ADVM
Trailing total returns as of 5/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADVM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADVM
Valuation Measures
Market Cap
214.63M
Enterprise Value
193.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
28.96
Price/Book (mrq)
2.57
Enterprise Value/Revenue
53.65
Enterprise Value/EBITDA
-1.63
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-32.14%
Return on Equity (ttm)
-88.43%
Revenue (ttm)
3.6M
Net Income Avi to Common (ttm)
-117.17M
Diluted EPS (ttm)
-11.60
Balance Sheet and Cash Flow
Total Cash (mrq)
96.53M
Total Debt/Equity (mrq)
89.90%
Levered Free Cash Flow (ttm)
-60.69M